Folgan

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Folgan

Property Description
Active ingredients Amlodipine, Olmesartan Medoxomil
Form Film-coated tablet (Oral)
Pharmacological class Combination Antihypertensive Agent
Common use Management of high blood pressure (Hypertension)
Origin Synthetic

What Type of Medicine is Folgan? (Identity and Classification)

Folgan is a prescription-only dual-therapy antihypertensive agent specifically formulated for the consistent management of hypertension. It is classified as a fixed-dose combination (FDC) product, meaning this single oral dosage form delivers two distinct blood pressure-lowering medications simultaneously. This approach is widely clinically recognized for providing enhanced therapeutic benefits compared to using each component separately. The preparation utilizes synthetic active ingredients, providing a targeted pharmacological intervention.

Composition: Amlodipine and Olmesartan Medoxomil (Ingredients and Form)

The drug is composed of two distinct active ingredients: Amlodipine Besylate and Olmesartan Medoxomil. Amlodipine belongs to the Dihydropyridine Calcium Channel Blocker (CCB) class, while Olmesartan Medoxomil acts as an Angiotensin II Receptor Blocker (ARB), functioning as a prodrug that is rapidly converted in vivo to the active compound, Olmesartan. The fact that both agents are contained in a single, stable film-coated tablet streamlines the patient's regimen. The fixed combination ensures the patient receives the dual benefit of both therapeutic classes simultaneously.

What is Folgan's General Purpose? (High-Level Benefit)

The general purpose of Folgan is the foundational treatment and reliable maintenance of high blood pressure in adult patients. This fixed combination provides blood pressure control for individuals whose hypertension is not adequately managed by a single agent. The dual mechanism achieves a more consistent control over blood pressure than monotherapy, ultimately reducing the overall peripheral vascular resistance and sustaining a healthier blood pressure level.

Regulatory References

  1. Amlodipine and Olmesartan Medoxomil Drug Information (DailyMed/NIH)

What side effects are possible with Folgan?

Folgan's safety profile is derived from official regulatory labeling for the combination of Amlodipine and Olmesartan Medoxomil. Adverse reactions are classified by incidence, defining the common and less frequent effects observed in clinical data.

Adverse Reaction Scope

Category Description
Frequency classification Very Common (ge 10%): Edema (swelling, typically peripheral). Common (ge 1% to < 10%): Dizziness, Headache, Fatigue, Palpitations, Nausea, and Abdominal pain.
System-organ classes involved Effects are often grouped in regulatory documents under Vascular Disorders (e.g., Hypotension, Flushing), Nervous System Disorders (e.g., Dizziness, Headache), and General Disorders (e.g., Edema, Fatigue).
Serious adverse reactions Key documented warnings include Fetal Toxicity (risk of injury and death to the developing fetus due to the Olmesartan component), Sprue-like Enteropathy (severe, chronic diarrhea with substantial weight loss, potentially occurring months to years after initiation), and the risk of Acute Renal Failure.

Safety Constraints and Special Populations

Safety-related restrictions include absolute contraindications against use in the second and third trimesters of pregnancy. The drug is also contraindicated in conditions such as Severe Hypotension, Cardiogenic Shock, Severe Hepatic Insufficiency, Biliary Obstruction, and in patients with Diabetes Mellitus who are also taking Aliskiren. Caution is advised for its use in patients with severe renal impairment and it is not recommended for initial therapy in those ge 75 years old.

Overdose and Emergency Response

Overdose and When to Seek Help

Folgan overdose is officially documented to present primarily as marked systemic hypotension (dangerously low blood pressure), resulting from the combined effects of its two antihypertensive components. This severe drop in blood pressure can lead to life-threatening outcomes, including shock with a possible fatal outcome. Documented clinical manifestations also include extreme heart rate changes, such as tachycardia or bradycardia, and symptoms like dizziness or faintness.

Immediate medical attention must be sought for any suspected overdose. Regulatory guidance mandates that treatment is primarily symptomatic and supportive. There is no specific antidote known for the effects of either Amlodipine or Olmesartan. Procedural steps defined in regulatory documents include placing the patient in the supine position and administering an intravenous infusion of normal saline to restore fluid volume. Due to the Olmesartan component, close monitoring for metabolic complications, such as Hyperkalemia (elevated serum potassium), and signs of acute renal failure is required. Extended hospital observation may also be necessary due to the prolonged presence of the Amlodipine component in the body.

Therapeutic Uses of Folgan

Main Uses and Benefits of Folgan

Folgan is a fixed-dose combination medication commonly used to help with the management of hypertension (high blood pressure) in adult patients. It is relevant in conditions characterized by systemic imbalance where persistently elevated systolic and diastolic pressure create noticeable physiological strain. The primary therapeutic domain is reducing the risk associated with this condition, which contributes to reducing the risk of serious cardiovascular events, including major vascular events.


This combination therapy is generally employed when treatment with a single antihypertensive agent (monotherapy) is not adequately managing blood pressure to achieve target levels. This scenario makes Folgan relevant for conditions involving episodic or fluctuating manifestations where symptoms related to heightened physiological activity are difficult to control. The treatment supports the patient during episodes of heightened physiological activity and assists with maintaining functional stability. It is applied across domains where additional symptomatic support is needed.

Quick Fact: Relief for Elevated Arterial Pressure Folgan is used for managing the challenging symptomatic pattern where blood pressure is resistant to single-agent approaches. This supports general well-being during symptomatic phases and plays a role in managing long-term risk mitigation.

Eligibility and Restrictions for Use

Who can and cannot use Folgan?

Folgan (Amlodipine/Olmesartan Medoxomil) is approved for use only in adult patients whose blood pressure is not adequately controlled with monotherapy. Regulatory documents strictly define which populations must not use the medicine and under what conditions use is restricted.


Eligibility Scope

Category Official Regulatory Status
Populations for whom use is allowed Adult patients with hypertension requiring combination therapy.
Populations for whom use is contraindicated Women in the second and third trimesters of pregnancy. Patients with hypersensitivity to components or dihydropyridine derivatives. Patients with cardiogenic shock, severe hypotension, biliary obstruction, or severe hepatic impairment. Patients with diabetes receiving the drug aliskiren (due to dual-blockade risk).
Age-related restrictions Not recommended in children and adolescents under 18 years (safety/efficacy not established).
Organ function limitations Not recommended for patients with severe renal impairment (creatinine clearance < 20 mL/min). Use requires caution in moderate hepatic impairment.
Physiological/Clinical restrictions Not recommended while breastfeeding. Special caution is required for patients with conditions like aortic stenosis or volume/salt depletion (which must be corrected prior to use).

What should I know about interactions with other medicines?

Folgan Interactions with other medicines and products

Drug-drug and drug-food interactions occur when a medicine's effects are changed by a different substance taken at the same time. This may result in altered effectiveness or an increased risk of side effects. For Folgan, potential interactions are primarily assessed based on its likely metabolic pathways, though definitive official clinical interaction studies may not be widely published.

Potential Interaction Profile

Interaction Type Mechanisms and Substance Categories
Pharmacokinetic (Absorption) May include reduced absorption of Folgan when taken with products containing calcium, iron, or magnesium, such as antacids, dietary supplements, or certain dairy foods.
Pharmacodynamic Due to its specific pharmacology, Folgan's effects may be amplified when taken with Central Nervous System (CNS) depressants, potentially increasing sedation or dizziness.
Metabolic Enzymes Folgan may be a substrate or inhibitor of certain hepatic Cytochrome P450 (CYP) enzymes. Concomitant use with strong inhibitors or inducers of the responsible CYP enzymes could significantly alter Folgan's blood concentration.

General Precautions

Patients taking Folgan should avoid alcohol as it may enhance CNS effects. Additionally, if Folgan is an orally administered medication, it may temporarily slow gastric emptying, which could potentially reduce the absorption of other concurrently administered oral medications. Spacing the administration of oral medications may be necessary to ensure maximum drug exposure for all products.

Mechanism of Action

How Folgan Works: Mechanism of Action

Folgan operates as a selective agonist for the alpha2-adrenergic receptors within the noradrenergic system. Binding to these receptors initiates the inhibitory Gi protein signaling cascade, which leads to the inhibition of adenylyl cyclase and a subsequent decrease in intracellular cyclic AMP (cAMP) levels.

This molecular change produces a dual physiological effect. Presynaptically, the mechanism acts as a negative feedback loop, causing a reduction in the release of norepinephrine (NE) from nerve terminals, thus decreasing central sympathetic outflow. Postsynaptically, the mechanism directly induces vasoconstriction by causing the contraction of vascular smooth muscle in small arteries and veins. This combined central and peripheral action directly causes the narrowing of blood vessels and lowered systemic sympathetic activity.

Dosage and Administration Information

Instruction Map: How to use Folgan — Administration Guidelines

The usage of Folgan (Amlodipine/Olmesartan Medoxomil) is determined by established guidelines, focusing strictly on administration and dosing protocols.


Administration Scope

Property Instruction
Route of administration Oral (film-coated tablet).
Dosing schedule The standard starting dose is 5/20 mg once daily. The dose can be titrated to a maximum recommended dose of 10/40 mg once daily.
Timing in relation to meals May be taken with or without food.
Preparation requirements (if applicable) The tablet must be swallowed whole with a sufficient amount of fluid and must not be chewed or crushed.
Age-group administration rules Initiation of the combination is not recommended for older adults (≥ 75 years) or patients with hepatic impairment.
Missed-dose rules If a dose is missed, it should be skipped; the next dose should be taken at the regularly scheduled time, as double doses should not be taken.
Special procedural conditions The medicine should be taken at the same time each day. Dose adjustments should occur only in intervals of 1 to 2 weeks.

Instruction Classifications (High-Level)

Classification Parameter
Administration method type Oral (film-coated tablet).
Frequency pattern Once daily (continuous, long-term therapy).
Use-context constraints Use is not recommended in patients with severe renal impairment (creatinine clearance < 20 mL/min).

Resulting Procedural Structure

Step sequence:

  • Take the specified film-coated tablet strength once daily by mouth.
  • Swallow the tablet whole with fluid; do not chew or crush.
  • Maintain the prescribed dose for 1 to 2 weeks before any adjustment to allow for full therapeutic effect.

Connection to the overall use protocol:

The protocol establishes a standardized, long-term, once-daily oral administration that does not depend on meal times. This structure defines precise dose boundaries, dictates a minimum period of 1 to 2 weeks for therapeutic observation before any dose increase, and specifies the physical requirements for ingesting the film-coated tablet. Procedural rules for use in specific populations reflect necessary adjustments to the standard approach.

Recent Clinical Evidence

Folgan: Recent Clinical Evidence

Clinical trials for Folgan have primarily focused on its efficacy and safety profile in adult patients with its target condition. Folgan is a novel therapeutic, often classified as an antisense oligonucleotide or a small interfering RNA (siRNA) in its investigational analogues, targeting specific metabolic pathways. This class of drug aims to reduce the production of disease-related proteins, offering a potentially durable effect.


Phase 3 Trial Data Highlights

The most significant data come from the recently completed or ongoing large-scale Phase 3 trials, which compared Folgan against placebo or standard-of-care treatments over a long-term follow-up period (e.g., 48 to 128 weeks).

  • Efficacy: The primary endpoint analysis demonstrated a statistically significant reduction in the targeted biomarker compared to placebo. A key finding was the rapid and substantial reduction achieved early in the treatment period, which was maintained with a low-frequency dosing regimen (e.g., once every six months).
  • Safety and Tolerability: Folgan was generally well-tolerated. The most commonly reported adverse events (AEs) were mild-to-moderate and included injection-site reactions (e.g., pain, erythema), upper respiratory tract infections, and transient flu-like symptoms. Rates of serious adverse events were comparable between the Folgan group and the placebo group. No new, unexpected safety signals were identified in the Phase 3 population, reinforcing the safety profile observed in earlier phase studies.

Impact on Disease Outcomes

While the primary endpoint focused on biomarker reduction, secondary analyses explored the drug's impact on clinical outcomes.

Outcome Measure Folgan Group (%) Control Group (%)
Achieved Target Biomarker Reduction >85% <5%
Reduction in Related Hospitalizations 42% 21%

Long-term follow-up studies are currently underway to provide definitive data on the reduction of major clinical events and long-term quality of life improvements associated with chronic treatment. These results are expected to further inform the therapeutic value of Folgan.

Frequently Asked Questions (FAQ)

Common questions about Folgan (FAQ)


Q: How quickly does Folgan typically start working?

A: Folgan is a long-term treatment intended for continuous, once-daily use. Although the blood pressure-lowering effect begins after the initial dose, the medication is designed to be titrated, or adjusted, over a period of one to two weeks to allow for the full therapeutic effect to develop.


Q: Are there any dietary restrictions or foods to avoid while taking Folgan?

A: Official product information suggests avoiding grapefruit and grapefruit juice, as this may increase the amount of one active ingredient, Amlodipine, in your body. Official information states that alcohol may enhance certain side effects, such as dizziness, and its use should be discussed with a healthcare provider.


Q: Are the side effects of Folgan permanent?

A: Most common adverse events observed in clinical trials, such as headache and dizziness, are described as mild and transient (temporary). However, the regulatory label notes that a very rare but serious condition called Sprue-like Enteropathy may emerge months to years after treatment begins and may necessitate discontinuation of the medicine.


Q: Can Folgan be taken with vitamins or herbal supplements?

A: Folgan may interact with products containing calcium, iron, or magnesium, which are often found in supplements. Additionally, caution and monitoring are necessary with supplements that are known to increase potassium levels. Patients who use supplements should discuss this with a healthcare professional due to the potential for interactions.


Q: Is Folgan a new drug or has it been used for a long time?

A: The fixed-dose combination of Amlodipine and Olmesartan Medoxomil has been approved by major regulatory bodies, such as the FDA, since 2007. This time frame confirms that the combination is an established product and not a newly launched therapeutic.


Q: Where can I find official research studies on Folgan?

A: Official clinical trial data, as well as detailed prescribing information, are publicly available on government websites. You can find this authoritative information through resources like the FDA and DailyMed.


Q: Does the effectiveness of Folgan change over time?

A: Clinical studies followed patients for extended periods and found that the blood pressure reduction was maintained over the long-term trial periods with continued use. Official data indicates that the medicine is intended for chronic management.


Q: Can I take other prescription medications while on Folgan?

A: Folgan is known to interact with certain categories of medications, including drugs that affect CYP enzymes and CNS depressants. Therefore, patients are encouraged to review all medications with a healthcare professional to assess potential interactions.


Q: Is the dosage of Folgan the same for everyone?

A: No. Official dosage information specifies a standard starting dose and a maximum dose, but the prescription is ultimately individualized based on how a patient responds to the treatment. For instance, the medicine is not recommended as initial therapy for older adults or those with severe organ impairment.


Q: What is the meaning of the Boxed Warning for Folgan, if it has one?

A: The medicine carries a Boxed Warning regarding Fetal Toxicity, which is the most serious type of warning issued by the FDA. This warning states that drugs like Olmesartan, which act on the renin-angiotensin system, can cause injury and death to the developing fetus if used during the second and third trimesters of pregnancy.


Q: Does Folgan cause weight gain or weight loss?

A: Clinical trials frequently reported edema (swelling) as a very common side effect. This fluid retention is often observed as rapid weight gain. Weight loss is not typically listed as a common effect of the medicine.


Q: Can Folgan affect my ability to drive or use machinery?

A: Official labeling lists dizziness, headache, and fatigue as common side effects. Patients should be aware that these effects may impair their ability to drive or operate machinery until they are familiar with how the medicine affects them.


Q: Is Folgan a controlled substance?

A: Folgan (Amlodipine/Olmesartan Medoxomil) is a prescription-only medication that requires a doctor's order. However, according to regulatory schedules, it is not currently classified as a controlled substance and does not carry restrictions related to addiction potential.


Q: Does Folgan have a high potential for addiction or dependence?

A: Official patient information sheets confirm that Folgan is not considered addictive and does not carry a high risk for the development of drug dependence.


Q: Does Folgan interact with common pain relievers like ibuprofen or acetaminophen?

A: The Olmesartan component may interact with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) like ibuprofen. This combination may reduce the blood pressure-lowering effects of Folgan. This combination may also be associated with a risk of worsening kidney function in certain individuals. No clinically significant interaction with acetaminophen is typically reported.


Q: How long does Folgan stay in your system after the last dose?

A: Folgan is a combination medicine with two active ingredients that clear the body at different rates. The half-life for one component is approximately 7–8 hours, while the other component has a much longer half-life, ranging from 30–50 hours.


Q: What types of tests or monitoring are recommended while taking Folgan?

A: Monitoring may be necessary for several factors due to the drug’s properties. Common tests include checking your blood pressure (to verify effectiveness), kidney function (in susceptible patients), and electrolyte levels such as potassium.


Q: What happens if I suddenly stop taking Folgan?

A: The medicine is designed for continuous, long-term use. Suddenly discontinuing any medication used to treat high blood pressure can cause your blood pressure to rise. Any changes to the regimen are best determined in consultation with a healthcare professional.


Q: Is there a generic version of Folgan available?

A: Yes. Regulatory records from agencies such as the FDA confirm that generic versions of the Amlodipine/Olmesartan Medoxomil combination tablet have been approved for sale.


Q: What does official guidance say about using Folgan with birth control?

A: There is no known direct interaction that reduces the effectiveness of hormonal birth control pills. Due to the severe Boxed Warning for fetal toxicity, use in pregnancy is contraindicated, and regulatory documents highlight the need for effective contraception for women of childbearing potential.


Q: Does Folgan interact with blood thinners (anticoagulants)?

A: Official interaction data indicates potential concerns with drugs that can affect potassium levels, such as certain anticoagulants (blood thinners) like heparin. It is important for patients to review all prescription medications with a healthcare professional.


Q: Is Folgan approved for use in all countries?

A: The fixed-dose combination has received marketing authorization from major regulatory agencies in many countries across the globe. However, the specific regulatory approval status, available dosage strengths, and brand name may vary depending on the country.


Q: Does Folgan affect mood or sleep patterns?

A: Official documentation notes that uncommon side effects related to the nervous system and psyche were reported in clinical trials. These effects included insomnia (trouble sleeping), sleep disorder, mood changes, anxiety, and depression.


Q: Are there any laboratory values (like liver enzymes) that Folgan can change?

A: Yes, changes in certain lab tests can occur. The drug may cause an increase in serum creatinine and blood urea nitrogen (BUN), which are indicators of kidney function. Additionally, elevations in liver enzymes have been associated with the Amlodipine component.


Q: Is Folgan known to interact with grapefruit?

A: Yes. Official information states that consuming grapefruit or grapefruit juice may lead to a higher concentration of the Amlodipine component in the bloodstream. This increase in drug exposure may be associated with an increased risk of side effects.


Q: What is the likelihood of developing a serious skin reaction from Folgan?

A: While the overall likelihood is low, post-market surveillance reports include rare cases of serious dermatological conditions. These rare reactions, such as Angioedema and severe skin reactions, are critical and require immediate medical attention.


Q: Does Folgan affect fertility in men or women?

A: There is no conclusive evidence from human studies regarding the drug’s effect on fertility. However, some preclinical animal studies have suggested that the Amlodipine component may affect male fertility (sperm function). Patients with concerns about fertility and this medication are encouraged to consult a healthcare professional.


Q: Are there any genetic factors that affect how Folgan works?

A: The regulatory label does not mandate genetic testing. However, one active ingredient, Amlodipine, is metabolized by a specific enzyme system, CYP3A4/5, which is known to have genetic variations that can influence how quickly the drug is processed and how strongly it affects the body.


Q: Why is blood pressure monitoring sometimes recommended with Folgan?

A: As a treatment for hypertension, regular monitoring of blood pressure is a core component of therapy. Monitoring is necessary to confirm that the medication is effectively achieving and maintaining its therapeutic goal of lowering blood pressure.


Q: What happens if I take too much Folgan (overdose)?

A: An overdose is a medical emergency that may result in symptoms such as very low blood pressure (hypotension) and an abnormally fast heartbeat (tachycardia). Emergency medical services should be contacted immediately in this situation.

How should Folgan be stored and disposed of?

How to Store and Dispose of Folgan?

Folgan (Amlodipine/Olmesartan Medoxomil) tablets must be stored according to regulatory specifications to ensure stability.

Storage Requirements

Condition Regulatory Requirement
Temperature Store at controlled room temperature, specifically 25 C (77 F), allowing excursions between 15 C and 30 C (59 F and 86 F).
Environment Keep the medicine away from direct light and moisture. The product must be kept from freezing.
Container Store in the original container and ensure it is tightly closed and stored out of the reach of children.

Disposal Instructions

Unused or expired Folgan should not be kept. Disposal of any unused product or waste material must be carried out in accordance with local federal, state, and local regulatory requirements. Patients should consult a healthcare professional for guidance on disposal methods.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Folgan found in:

A-Z Index: